Real-life Pan-HER-blockade With Neratinib
Status: ACTIVE_NOT_RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Neoplasm
Interventions: DRUG: Neratinib
Sponsor: Pierre Fabre Pharma GmbH
Collaborators: iOMEDICO AG|Pierre Fabre Pharma Austria|Pierre Fabre Pharma AG